

**3. *Objection to the Inventor's Declaration***

The Examiner objected to the declaration of Howard Grey because of a change that was not initialed on the originally-filed declaration. Applicants submit herewith a new declaration signed and dated by Dr. Grey. Applicants therefore respectfully request withdrawal of the objection.

**4. *Rejection under 35 U.S.C. § 112***


The Examiner rejected claims 80-83 as allegedly failing to meet the written description requirement. Applicants strongly disagree because the peptides of the claims are clearly described in the application, albeit using different variables. However, to speed prosecution, claims 80-83 are canceled. Applicants therefore respectfully request withdrawal of the objection.

**4. *Obviousness-type double patenting rejection***

The Examiner rejected claims 78-79 under the judicially created doctrine of obviousness-type double patenting in view of U. S. Patent No. 5,736,142. Applicants herein submit a terminal disclaimer of the term of any patent granted on the instant application over U.S. Patent No. 5.736,142. Applicants note that the filing of a terminal disclaimer to obviate a rejection based on non-statutory double patenting is not an admission of the propriety of the rejection. *See*, MPEP §804.02. Applicants respectfully request that the rejection be withdrawn.

CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested. If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 415-576-0200.

Respectfully submitted,  
  
Matthew E. Hirsch  
Reg. No. 47,651

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: 415-576-0200  
Fax: (415) 576-0300  
MEH:meh  
SF 1457969 v1

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**IN THE SPECIFICATION:**

Please amend the CROSS-REFERENCE TO RELATED APPLICATIONS on page 1, line 10 as follows:

--This application is a continuation-in-part of U.S. Patent Application No. 08/788,822, filed January 23, 1997, now [pending] U.S. Patent No. 6413935, issued July 2, 2002, which application claims benefit of U.S. Provisional Application No. 60/010,510, filed January 24, 1996, now abandoned. This application is also a continuation-in-part of U.S. Patent Application No. 09/310,462, filed May 12, 1999, now [pending] abandoned, which application is a continuation-in-part of U.S. Patent Application No. 08/485,218, filed June 7, 1995, now abandoned, which application is a continuation-in-part of U.S. Patent Application No. 08/305,871, filed September 14, 1994, now Patent No. 5,736,142, which application is a continuation-in-part of U.S. Patent Application No. 08/121,101, filed September 14, 1993, now abandoned. Each of these applications is incorporated herein by reference for all purposes.--

Please amend the paragraph beginning on page 19, line 28 as follows:

--A large number of cells with defined MHC molecules, particularly MHC class II molecules, are known and readily available from, for instance, the American Type Culture Collection (*see, e.g.*, online catalog on the worldwide web at [www.jatcc.org; "Catalogue of Cell Lines and Hybridomas," 8th edition (1994) Manassas, VA).--